🇺🇸 FDA

Intelligence · Clinical Pipeline

Autoimmune & immunology · Phase I

Autoimmune & immunology programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs
167

Quick answer

Autoimmune & immunology Phase I programs: NovaPharmaNews indexes 167 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 3 of 4

  1. IASO206 injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Autoimmune Hemolytic Anemia

    phase 1 mab active

    1 trial

  2. Ixazomib

    Takeda

    Lupus Nephritis

    phase 1 small molecule terminated

    1 trial

  3. JADE201

    Jade Biosciences

    Rhematoid Arthritis

    phase 1 small molecule active

    1 trial

  4. JANX011

    Janux Therapeutics

    Autoimmune

    phase 1 small molecule active

    1 trial

  5. LCAR-AIO T cells

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Autoimmune Diseases

    phase 1 mab terminated

    1 trial

  6. LCAR-AIO T cells

    Nanjing Legend Biotech Co.

    Systemic Lupus Erythematosus (SLE)

    phase 1 mab active

    1 trial

  7. LD and GC012F CAR-T Cell Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rheumatoid Arthritis

    phase 1 small molecule active

    1 trial

  8. LUCAR-DKS1 NK cells

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Autoimmune Diseases

    phase 1 mab active

    1 trial

  9. LUCAR-G79 T cells

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Autoimmune Diseases

    phase 1 mab active

    1 trial

  10. LUCAR-G79D T cells

    Nanjing Legend Biotech Co.

    Systemic Lupus Erythematosus (SLE)

    phase 1 mab active

    1 trial

  11. LVIVO-TaVec400 product

    Nanjing Legend Biotech Co.

    Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE)

    phase 1 mab active

    1 trial

  12. LX3305

    LEXICON PHARMACEUTICALS, INC.

    Rheumatoid Arthritis

    phase 1 small molecule completed

    1 trial

  13. Linperlisib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Autoimmune Hemolytic Anemia

    phase 1 small molecule terminated

    1 trial

  14. MC-1-50

    Chongqing Precision Biotech Co., Ltd

    Systemic Lupus Erythematosus (SLE)

    phase 1 mab active

    1 trial

  15. MDGN-002

    Avalo Therapeutics

    Crohn Disease

    phase 1 small molecule terminated

    1 trial

  16. MK-2420 SAD Study

    Merck Sharp and Dohme

    Rheumatoid arthritis

    phase 1 other active

    1 trial

  17. Methotrexate

    Sana Biotechnology

    Chronic Plaque Psoriasis

    phase 1 small molecule active

    1 trial

  18. Methotrexate - Amneal

    Amneal Pharma Europe Ltd

    Psoriasis

    phase 1 small molecule active

    1 trial

  19. Methotrexate PK (in combination with Novobiocin) in RA patients

    Lacuna Pharma Pty Ltd

    Rheumatoid arthritis

    phase 1 other active

    1 trial

  20. Modified Gegen Qinlian Decoction

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ulcerative Colitis

    phase 1 small molecule active

    1 trial

  21. Multiple Ascending Doses of BMS-986326 in Participants with Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic Lupus Erythematosus

    Bristol-Myers Squibb Australia Pty Ltd

    Subacute Cutaneous Lupus Erythematosus, Discoid Lupus Erythematosus, Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  22. No Intervention

    Takeda

    Rheumatoid Arthritis

    phase 1 other completed

    1 trial

  23. Obecabtagene autoleucel (obe-cel)

    Autolus GmbH

    Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial

  24. PET study of changes in [11C]AZ14132516 uptake following administration of multiple AZD7798 doses to patients with Crohn’s disease.

    AstraZeneca AB

    Crohn's disease

    phase 1 other active

    1 trial

  25. PIPE-791

    Contineum Therapeutics

    Chronic Osteoarthritis Pain

    phase 1 small molecule completed

    1 trial

  26. PTOC1

    Chongqing Precision Biotech Co., Ltd

    Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial

  27. Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (risankizumab biosimilar), with EU-approved Skyrizi®, and US licensed Skyrizi® in Healthy Adult Participants

    Lacuna Pharma Pty Ltd

    Active psoriatic arthritis, Moderately to severely active Crohn’s disease, Moderate-to-severe plaque psoriasis, Moderately to severely active ulcerative colitis

    phase 1 other active

    1 trial

  28. Phase 1 study on SAR443122 bioavailability and food effect in healthy adults

    Sanofi-aventis Healthcare Pty Ltd

    Colitis ulcerative

    phase 1 other active

    1 trial

  29. Placebo

    Nektar Therapeutics UK Limited

    Psoriasis

    phase 1 small molecule completed

    1 trial

  30. QT-019C

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    SLE - Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial

  31. REGN88

    Regeneron UK Limited

    Rheumatoid Arthritis

    phase 1 mab completed

    3 trials

  32. RO7507062

    Hoffmann-La Roche

    Systemic Lupus Erythematosus

    phase 1 small molecule active

    1 trial

  33. Rilonacept

    Regeneron UK Limited

    Autoimmune Neurosensory Hearing Loss (ANSHL)

    phase 1 small molecule active

    1 trial

  34. SC291

    Sana Biotechnology

    Lupus Erythematosus

    phase 1 mab active

    1 trial

  35. SER-287

    Seres Therapeutics

    Ulcerative Colitis

    phase 1 small molecule completed

    1 trial

  36. SSGJ-613

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Systemic Juvenile Idiopathic Arthritis

    phase 1 small molecule active

    1 trial

  37. SSGJ-613

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Arthritis, Gouty

    phase 1 small molecule active

    1 trial

  38. STRATIFY; Near-infrared fluorescence molecular imaging of adalimumab-800CW to elucidate the drug distribution throughout inflamed tissue in inflammatory bowel disease and rheumatoid arthritis

    Disc Medicine

    Crohn's disease, Spondyloarthritis, Rheumatoid arthritis, Ulcerative colitis

    phase 1 other active

    1 trial

  39. Safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous and subcutaneous multiple rising doses of BI 765250 versus placebo in trial participants with moderate to severe plaque psoriasis (double-blind, randomised, placebo-controlled, parallel-group design)

    Boehringer Ingelheim

    Plaque psoriasis

    phase 1 other active

    1 trial

  40. Sargramostim

    Ultragenyx UK Limited

    Autoimmune Pulmonary Alveolar Proteinosis

    phase 1 small molecule completed

    1 trial

  41. Signature Cord Prime

    Forteo

    Osteoarthritis, Knee

    phase 1 mab active

    1 trial

  42. Single and multiple ascending dose of ZP9830 in healthy participants

    Zealand Pharma A/S

    Autoimmune diseases

    phase 1 other active

    1 trial

  43. Spesolimab

    Boehringer Ingelheim

    Psoriasis

    phase 1 small molecule completed

    1 trial

  44. Study of GS-0151 in Participants With Rheumatoid Arthritis

    Gilead Sciences Pty Limited

    Rheumatoid Arthritis

    phase 1 other active

    1 trial

  45. Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR

    Novartis Pharmaceuticals

    Polymyalgia rheumatica (PMR), Giant cell arteritis (GCA)

    phase 1 other active

    1 trial

  46. TAK-007

    Takeda

    Refractory Lupus Nephritis

    phase 1 mab terminated

    1 trial

  47. TAK-079

    Takeda

    Autoimmune Disease

    phase 1 small molecule completed

    1 trial

  48. TAK-079

    Takeda

    Systemic Lupus Erythematosus

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many autoimmune & immunology Phase I programs exist?

167 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.